| Pair Name | Alantolactone, Erlotinib | ||
| Phytochemical Name | Alantolactone (PubChem CID: 72724 ) | ||
| Anticancer drug Name | Erlotinib (PubChem CID: 176870 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Alantolactone, Erlotinib | |||
| Disease Info | [ICD-11: 2C10.Z] | Pancreatic cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | STAT3 | hsa6774 |
| In Vitro Model | PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 |
| BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0186 | |
| AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0152 | |
| In Vivo Model | BxPC-3 cells (1×10⁶) in 0.1 mLPBS were injected subcutaneously into the right flank of eachmouse. | |||
| Result | Our results suggested that Alantolactone could sensitize human pancreatic cancer cells to EGFR inhibitors possibly through down-regulating the STAT3 signaling. Alantolactone, when combined with other EGFR targeted agents, could be further developed as a potential therapy for pancreatic cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Mol Carcinog. 2019 Apr;58(4):565-576. doi: 10.1002/mc.22951. | Click |
